In this episode of The GLP-1 Podcast Show, I speak with Dr. Michael Nauck, Head of Clinical Research at the Diabetes Division of St. Josef-Hospital, Ruhr-University Bochum, Germany. We explore the early discoveries behind incretin hormones, the development of GLP-1–based therapies, and their expanding role in diabetes, obesity, and cardiovascular care. Dr. Nauck also discusses the next generation of dual and triple agonists shaping obesity medicine. Listen now on all major platforms.
“For the first time, weight loss medications, like GLP-1, achieved meaningful reductions without serious safety concerns.”
Meet the guest: Dr. Michael Nauck is Head of Clinical Research at the Diabetes Division, St. Josef-Hospital, Ruhr-University Bochum, Germany. His pioneering work on incretin hormones established the scientific foundation for GLP-1–based therapies in type 2 diabetes. With a research focus on metabolic regulation and cardiovascular outcomes, Dr. Nauck continues to advance innovation in endocrinology and obesity care.
Podden och tillhörande omslagsbild på den här sidan tillhör
Wisenetix. Innehållet i podden är skapat av Wisenetix och inte av,
eller tillsammans med, Poddtoppen.
